Values and preferences towards medical cannabis among people living with chronic pain: a mixed-methods systematic review

Linan Zeng, Lyubov Lytvyn, Xiaojin Wang, Natasha Kithulegoda, Silvana Agterberg, Yaad Shergill, Meisam Abdar Esfahani, Anja Fog Heen, Thomas Agoritsas, Gordon H Guyatt, Jason W Busse

ABSTRACT

Objective To explore values and preferences towards medical cannabis among people living with chronic pain.

Design Mixed-methods systematic review.

Data sources We searched MEDLINE, EMBASE and PsycINFO from inception to 17 March 2020.

Study selection Pairs of reviewers independently screened search results and included qualitative, quantitative and mixed-methods studies reporting values and preferences towards medical cannabis among people living with chronic pain.

Review methods We analysed data using meta-narrative synthesis (quantitative findings were qualitised) and tabulated review findings according to identified themes. We used the Grading of Recommendations Assessment, Development and Evaluation approach to assess certainty of evidence.

Results Of 1838 initial records, 15 studies proved eligible for review. High to moderate certainty evidence showed that patient’s use of medical cannabis for chronic pain was influenced by both positive (eg, support from friends and family) and negative social factors (eg, stigma surrounding cannabis use). Most patients using medical cannabis advantaged products with balanced ratios of tetrahydrocannabinol (THC) and cannabidiol (CBD), or high levels of CBD, but not high THC preparations. Many valued the effectiveness of medical cannabis for symptom management even when experiencing adverse events related to concentration, memory or fatigue. Reducing use of prescription medication was a motivating factor for use of medical cannabis, and concerns regarding addiction, losing control or acting strangely were disinterested. Out-of-pocket costs were a barrier, whereas legalisation of medical cannabis improved access and incentivised use. Low to very low certainty evidence suggested highly variable values towards medical cannabis among people living with chronic pain. Individuals with pain related to life-limiting disease were more willing to use medical cannabis, and preferred oral rather than inhaled administration.

Conclusions Our findings highlight factors that clinicians should consider when discussing medical cannabis. The variability of patients’ values and preferences emphasise the need for shared decision making when considering medical cannabis for chronic pain.

INTRODUCTION

Chronic pain is the major cause of non-fatal disease burden worldwide, and is estimated to affect one in five adults in the general global population and one in three in low-income and middle-income countries. Opioids are commonly prescribed for chronic pain; however, increasing awareness of modest benefits and risks of addiction, overdose and death have generated interest for alternative management strategies. Medical cannabis, whose two most studied active ingredients are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), is one such therapeutic alternative. Moreover, the legalisation of medical cannabis among more than 30 countries has increased access for people living with chronic pain who are considering this option. Accordingly, physicians are increasingly faced with questions from patients about the potential role of medical cannabis in managing their pain.

Strengths and limitations of this study

- Consideration of complementary bodies of evidence (qualitative, quantitative and mixed methods) and use of the Grading of Recommendations Assessment, Development and Evaluation approach to assess the certainty of evidence provide greater confidence in the interpretation of results.
- Most eligible studies are from high-income countries, reflecting values and preferences of patients living in better healthcare service systems with health insurance coverage. The generalisability of our findings to other populations is uncertain.
- Studies eligible for this review failed to consistently report participants’ socioeconomic status, educational level and religious beliefs, limiting exploration of the impact of these characteristics on values and preferences towards medical cannabis for chronic pain.
Physicians who seek guidance from current clinical practice guidelines regarding medical cannabis for chronic pain will find recommendations to be inconsistent. As examples, the UK’s National Institute for Health and Care Excellence (NICE) recommends against prescribing cannabis-related products for chronic pain, citing its high cost and inadequate supporting evidence. The American Academy of Neurology recommends an oral cannabis extract containing both THC and CBD as having the highest level of empirical support as a treatment for chronic pain associated with multiple sclerosis. These guidelines, and others, have neglected to systematically identify and incorporate target patients’ values and preferences, which may affect their findings.

Understanding patients’ values and preferences, defined as patient-important desirable and undesirable consequences weighed when making a recommendation, can improve the trustworthiness of recommendations. Therefore, we conducted a systematic review investigating values and preferences towards the use of medical cannabis among people living with chronic pain. This systematic review is part of the BMJ Rapid Recommendations project, a collaborative effort from the MAGIC Evidence Ecosystem Foundation (www.magicvidence.org) and the British Medical Journal. This systematic review informed a parallel guideline published on bmj.com and MAGICApp.

METHODS
We registered our study protocol on the Open Science Framework (https://osf.io/5d72w) and adhered to the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement.

Data source and searches
We searched MEDLINE, EMBASE and PsycINFO from inception to 17 March 2020, using a combination of search filters for retrieving studies on values and preferences towards cannabis use among people living with chronic pain (online supplemental appendix 1). We reviewed reference lists of all included studies and relevant reviews to identify additional eligible studies.

Study selection
We included quantitative, qualitative (including survey research that only reported qualitative findings) and mixed-methods studies that reported values and preferences of people living with chronic cancer or non-cancer pain, or their carers, on: (1) relative values or importance of outcomes related to medical cannabis use (eg, improvements in pain and function, side effects) for chronic pain (defined as pain lasting 3 months or longer); (2) formulation of medical cannabis (eg, administration routes, ingestion methods, ratios of THC to CBD) or (3) factors that influence the decision to use medical cannabis. If studies enrolled both acute and chronic pain patients, we considered them eligible if they reported outcomes of chronic pain patients separate from others, or if at least 80% of patients were affected by chronic pain.

We excluded studies that: (1) did not elicit data from patients or carers directly (eg, data elicited from health providers; information from databases of health records); (2) only reported health state values or quality of life of people living with chronic pain, not related to use of medical cannabis; (3) only reported correlation analyses of associations among demographic variables, other patient characteristics and medical cannabis use for chronic pain; (4) case studies with less than 10 patients; (5) studies published in languages other than English; or (6) abstracts and literature reviews.

Before beginning each phase of the review process, we conducted calibration exercises in which reviewers assessed the same two articles and discussed any disagreements, leading to clarification and a common understanding of criteria and process. After calibration, six paired reviewers (LZ and XW, NK and SA, YS and MAE) independently screened titles and abstracts of all retrieved references, and the full text of articles deemed potentially eligible. We resolved disagreements by discussion or consultation with an adjudicator (LL).

Data collection and risk of bias assessment
Three pairs of reviewers (LZ and XW, NK and SA, YS and MAE) extracted data from eligible studies, independently and in duplicate, for research questions, population characteristics, design and methods of data collection, risk of bias or methodological limitations and main findings (online supplemental appendix 2). For main findings, we selected two eligible articles per study design, identified key themes addressed in the studies, and then coded the themes as different categories for main findings in the data abstraction form (online supplemental appendix 2). We resolved disagreements through discussion to reach consensus, or in consultation with an adjudicator (LL).

For quantitative studies, we used Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidance for studies of values and preferences to assess risk of bias of individual studies (online supplemental appendix 3). For qualitative studies, we used the Critical Appraisal Skills Programme checklist to assess methodological reporting quality of individual studies (online supplemental appendix 4).

Data synthesis and analysis
Using an iterative process, we compared themes of the categories identified across all studies and developed analytical themes. We applied critical meta-narrative synthesis, a modified form of critical interpretive synthesis, to transform quantitative into qualitative data using systematic profiles and critical questions that are asked to further extract narratives from the data. To facilitate this transformation, we applied four types of profiles to transform the extracted quantitative data that had the potential to be qualified, or converted into...
narratives (table 1).12 16 By using inductive content analysis we synthesised the qualitised findings to produce review findings which addressed the key themes.

**Certainty of evidence**

For review findings from quantitative studies, we assessed the certainty of evidence according to the five GRADE domains (ie, risk of bias, imprecision, inconsistency, indirectness and small study effects).13 17 18 For review findings from qualitative studies, we assessed the certainty of evidence according to the five GRADE Confidence in the Evidence from Reviews of Qualitative Research domains (ie, methodological limitations, relevance, coherence, adequacy and dissemination bias).19 We initially considered the certainty of evidence as high, and if serious or several minor or moderate concerns were detected in one or more domains, we rated down certainty of evidence by one or more levels to moderate, low or very low.

**Patient and public involvement**

We engaged three people living with chronic pain, one of whom used medical cannabis, to review our findings and advise if they were consistent with their experiences. Led by the MAGIC Evidence Ecosystem Foundation, a BMJ RapidRec panel of clinicians, methodologists and persons with lived experience of chronic pain were responsible for developing clinical practice recommendations for

<table>
<thead>
<tr>
<th>Systematic profiles*</th>
<th>Critical questions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Modal profile</strong></td>
<td>The most frequently occurring attributes</td>
</tr>
<tr>
<td><strong>Average profile</strong></td>
<td>Average of the particular variables</td>
</tr>
<tr>
<td><strong>Comparative profile</strong></td>
<td>A comparison of key outcomes</td>
</tr>
<tr>
<td><strong>Holistic profile</strong></td>
<td>A combination of the modal, average and comparative profiles</td>
</tr>
</tbody>
</table>

### Table 1 Critical meta-narrative synthesis: from quantitative data to narratives

<table>
<thead>
<tr>
<th>Systematic profiles*</th>
<th>Focus</th>
<th>Example</th>
<th>Critical questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modal profile</td>
<td>The most frequently occurring attributes</td>
<td>When asked to state the preference for route of administration: 86% (69/80) patients were comfortable with an oral form (pills, drops or added to food), while 15% (12/80) chose smoking. <strong>This was qualitised as:</strong> Most patients stated preference for oral formulations, while a minority preferred inhaled products.</td>
<td>What is this study trying to say about patients’ values? Are patients’ values and preferences explicitly identified? If so, what are they? How do participants answers to the questions provide insight into patients’ values and preferences, and their influence on the choice of treatment for chronic pain? How different (or similar) are patients’ and carers’ perspectives on medical cannabis for chronic pain? Are there other individual or contextual factors (eg, age, gender, socioeconomic status) that influence patients’ values and preferences towards medical cannabis for chronic pain?</td>
</tr>
<tr>
<td>Average profile</td>
<td>Average of the particular variables</td>
<td>Patients’ concerns regarding medical cannabis using a 10-point scale (0=not concerned, 10=extremely concerned) were, in order of important: side effects (mean=7.0±2.9), addiction (6.6±3.2), tolerance (6.2±3.2), losing control or acting strangely (6.2±3.3), and what family and friends may think (3.9±3.8). <strong>This was qualitised as:</strong> Patients were generally most concerned about the side effects of medical cannabis, followed by addiction, tolerance, losing control or acting strangely, and what family and friends may think.</td>
<td></td>
</tr>
<tr>
<td>Comparative profile</td>
<td>A comparison of key outcomes</td>
<td>Patients were asked to rate their values and concerns regarding use of cannabis (strongly agree, agree, disagree, strongly disagree and don’t know). Significantly more males, versus women, were concerned about cannabis being addictive (p=0.031), leading to the use of more harmful substances (p=0.036), and causing an inability to think clearly (p=0.008). <strong>This was qualitised as:</strong> Compared with females, significantly more males were concerned about cannabis being addictive, leading to the use of more harmful substances, and causing an inability to think clearly.</td>
<td></td>
</tr>
<tr>
<td>Holistic profile</td>
<td>A combination of the modal, average and comparative profiles</td>
<td>Patients were asked to rate their willingness to use medical cannabis on a 0–10 point scale (0=extreme unwillingness to 10=extreme willingness). Greater unwillingness was associated with higher age (bivariate correlation coefficient(r)=0.40; p=0.001), but not with pain intensity or duration, or sex. <strong>This was qualitised as:</strong> Higher age was related to more unwillingness to use medical cannabis.</td>
<td></td>
</tr>
</tbody>
</table>
medical cannabis and chronic pain. Three patient partners were full members of the guideline panel and received training and support to optimise contributions throughout the guideline development process. The panel developed recommendations using the GRADE framework, available online through the MAGICapp, and considered evidence from systematic reviews on the effectiveness of medical cannabis, adverse events related to medical cannabis, opioid substitution with medical cannabis, and this review of patients’ values and preferences regarding medical cannabis to manage chronic pain.

RESULTS
Our search retrieved 1838 records, of which 102 were deemed potentially eligible based on titles and abstracts. After full-text screening, 15 studies (reported in 16 articles) proved eligible for review, including nine quantitative studies, five qualitative studies and one mixed-method study (figure 1, online supplemental appendices 5 and 6).

Study characteristics
Of the 15 studies, nine were conducted in the USA, two in the UK, two in Israel, one in Canada and one in Australia. Four studies were conducted between 2000 and 2009, and 11 were conducted between 2010 and 2019. The number of participants ranged from 34 to 1514 among quantitative studies, 18 to 150 in the qualitative studies, and 984 were enrolled in the mixed method study. All 15 studies included only chronic pain patients; no caregivers were enrolled (online supplemental appendix 5).

Among the nine quantitative and one mixed method studies, four were at serious and one at critical risk of bias due to lack of valid representation of the outcomes (eg,
beneficial or harmful outcomes of medical cannabis), low response rate (less than 80%) and lack of reporting on how the authors confirmed participants’ understanding of the measurement techniques (eg, questionnaire) (online supplemental appendix 7). Among the five qualitative studies, only one was at serious risk of bias due to inadequate research design and data collection, and lack of reporting on whether the relationship between researchers and participants had been adequately considered (online supplemental appendix 8).

Findings
We identified two key themes: values and preferences towards medical cannabis for chronic pain (seven quantitative studies (2185 participants)), three qualitative studies (95 participants) and one mixed-method study (984 participants) and factors that influenced patient’s decisions regarding use of medical cannabis (seven quantitative studies (4998 participants), five qualitative studies (263 participants) and one mixed-method study (984 participants)) (table 2, online supplemental appendix 9).

Use of medical cannabis for chronic pain
Low certainty evidence showed that patients had mixed levels of willingness to use medical cannabis and most patients who used medical cannabis reported positive attitudes toward its use. Most patients with advanced life-limiting illnesses were comfortable using cannabis for pain,25 while some other patients with chronic pain were unwilling or ambivalent about medical cannabis use.26 Non-white patients with advanced illness were more concerned about medical cannabis compared with white patients, but they remained comfortable using medical cannabis.25 People living with chronic pain who used medical cannabis believed it was effective for reducing their pain25 27 31 34 and allowed them to reduce use of prescribed medications.27 Two qualitative studies found similar results.22 28

Medical cannabis versus other pain medicines
Patients with histories of substance use preferred medical cannabis over prescription opioids (low certainty).23 Some patients endorsed that medical cannabis was safer than other analgesics, and such beliefs were more prevalent among non-Christians and patients with college education or higher (very low certainty).25

Different preparations of medical cannabis
Moderate certainty evidence showed that most people living with chronic pain preferred using a blend of indica and sativa to manage their condition.21 There was no difference in the preference of cannabis strain between males and females, those who used cannabis for medical purposes only and those who endorsed medical and recreational use, or between novice and experienced users.21

Most patients preferred medical cannabis products with either balanced ratios of THC:CBD (37%) or high CBD formulations (46%) and only a minority (17%) preferred high THC products (Moderate certainty).21 33 Specifically, women, novice users or those who endorsed use of cannabis for medical purposes only were more inclined to choose products with low THC and high CBD ratios, while males, those endorsing use of cannabis for both medical and recreational purposes, and experienced users preferred products with equal ratios of THC:CBD.21

Factors influencing the decision to use medical cannabis
High to moderate certainty evidence showed that most people living with chronic pain used medical cannabis for symptom relief.20 22 23 26 35 Specifically, patients viewed medical cannabis as an effective approach to managing pain,20 22 23 35 sleep, appetite and nausea.20 35 Patients also reported that cannabis improved their emotional and mental well-being by reducing anxiety, depression and stress,20 35 and increased their ability to focus and function.20 Most patients reported that cannabis facilitated a state of relaxation in which pain remained present but was easier to tolerate.20

Moderate certainty evidence showed that factors related to patients’ unwillingness to use medical cannabis include major side effects (eg, losing control or acting strangely),20 23 26 27 31 34 35 addiction or tolerance,26 27 31 34 35 and negative social consequences (eg, stigma).20 25 26 31 32 34 35 Older age was associated with greater hesitancy to use medical cannabis, as was concerns about negative opinions from others which might lead to relationship problems or disagreements with loved ones.20 26 31 34 Some patients reported that stigma affected their comfort in asking healthcare providers about cannabis as a treatment option, and their willingness to use medical cannabis in a public setting.32 Moderate certainty evidence showed that cost, legal status, and accessibility of medical cannabis also influenced use.20 23 25 31 34 35

Factors influencing the choice of different preparations of medical cannabis
Low certainty evidence suggested that most patients chose medical cannabis products based on cannabinoid content (ie, THC or CBD potency, ratio of THC and CBD), recommendations from dispensary employees, described effects (eg, pain relief), strain of cannabis plant (ie, sativa, indica, hybrid), smell or varietal name.21–23 28 30 A higher proportion of males selected cannabis products based on cannabinoid content, cannabis variety, visual properties and smell, while a higher proportion...
### Table 2  Review findings and certainty of evidence

<table>
<thead>
<tr>
<th>Review findings*</th>
<th>Type of research evidence: Reference no</th>
<th>Certainty of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Values and preferences towards medical cannabis for chronic pain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Use of medical cannabis for chronic pain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic pain patients had mixed levels of comfort or willingness to use medical cannabis.</td>
<td>Quantitative: 25, 26, 27 Qualitative: 22</td>
<td>Low: Risk of bias and indirectness Low: Minor concerns about relevance, serious adequacy concerns</td>
</tr>
<tr>
<td>Most patients who use medical cannabis had a positive attitude towards its use for pain relief.</td>
<td>Quantitative: 25, 27, 29, 31, 34 Qualitative: 28</td>
<td>Low: Risk of bias and indirectness Moderate: Serious adequacy concerns</td>
</tr>
<tr>
<td><strong>Medical cannabis over other pain medicines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with chronic pain and substance use histories preferred medical cannabis over prescription opioids.</td>
<td>Qualitative: 23</td>
<td>Low: Moderate methodological limitations and moderate adequacy concerns</td>
</tr>
<tr>
<td>Some patients believed that medical cannabis is safer than morphine and other strong pain killers.</td>
<td>Quantitative: 25</td>
<td>Very low: Risk of bias, indirectness and imprecision</td>
</tr>
<tr>
<td><strong>Different preparations of medical cannabis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabis variety (ie, sativa, indica, hybrid)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Most patients preferred medical cannabis with a blend of indica and sativa, regardless of gender, reasons for use, and cannabis experience level.</td>
<td>Quantitative: 21</td>
<td>Moderate: Risk of bias</td>
</tr>
<tr>
<td><strong>Cannabis content (ie, THC or CBD potency, ratio of THC and CBD)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A balanced ratio of THC:CBD was the most preferred preparation, but gender, reason for use, and cannabis experience level influenced patients’ preference for cannabis ratio.</td>
<td>Quantitative: 21, 33</td>
<td>Moderate: Risk of bias</td>
</tr>
<tr>
<td><strong>Cannabis administration route</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender, reason for use and cannabis experience level influenced patients’ preferred cannabis administration routes.</td>
<td>Quantitative: 21 Mixed method: 35</td>
<td>Moderate: Risk of bias</td>
</tr>
<tr>
<td>Most patients with advanced life-limiting illness preferred an oral form (non-inhaled) of medical cannabis.</td>
<td>Quantitative: 25</td>
<td>Low: Risk of bias and imprecision</td>
</tr>
<tr>
<td><strong>Factors that influenced patient’s decision regarding use of medical cannabis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factors influenced the choice of medical cannabis use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Most patients used medical cannabis because it improved symptoms associated with pain, mental health and other medical conditions.</td>
<td>Quantitative: 20, 22, 23, 28 Mixed method: 35</td>
<td>High Moderate: Risk of bias</td>
</tr>
<tr>
<td>Most patients were motivated to use medical cannabis to reduce use of prescription medication.</td>
<td>Quantitative study: 27 Qualitative study: 22</td>
<td>Moderate: Risk of bias Moderate: Moderate adequacy concerns</td>
</tr>
<tr>
<td>The majority of patients expressed that their cannabis use was influenced by positive social consequences, such as social support from friends and family.</td>
<td>Quantitative: 25, 31,34</td>
<td>Moderate: Risk of bias</td>
</tr>
<tr>
<td>Most patients expressed concerns with using medical cannabis, and described a range of adverse effects.</td>
<td>Quantitative: 26, 27, 31, 34 Mixed method: 35 Qualitative : 20, 23</td>
<td>Moderate: Risk of bias Moderate: Moderate methodological concerns</td>
</tr>
<tr>
<td>Most patients expressed that their cannabis use was influenced by negative social consequences, such as stigma.</td>
<td>Quantitative: 25, 26, 31, 4 Mixed method: 35 Qualitative: 20, 32</td>
<td>Moderate: Risk of bias Moderate: Moderate methodological limitations</td>
</tr>
<tr>
<td>The cost, legal status and accessibility of medical cannabis influenced patients’ decisions to use medical cannabis.</td>
<td>Quantitative: 24, 25, 31, 34 Mixed method: 35 Qualitative: 20, 23</td>
<td>Moderate: Risk of bias Moderate: Moderate methodological limitations</td>
</tr>
</tbody>
</table>

Continued
of females consulted with a medical professional when choosing cannabis products (moderate certainty).

Patients who used cannabis both medically and recreationally were more likely to select cannabis products based on cannabinoid content, cannabis variety, described effects, visual properties, smell, recommendations from friends and the product name, while those who only used cannabis medically were more likely to prioritise recommendations from dispensary employees or medical professionals (moderate certainty).

**DISCUSSION**

Values and preferences among patients with chronic pain towards the use of medical cannabis are highly variable. Improvement of symptoms and reduction of prescription medications are important factors that positively influence patients’ decision to use medical cannabis, while concerns about addiction, losing control, acting strangely and negative social consequences are associated with unwillingness to use medical cannabis. Cost, legal status and accessibility are also important factors. Patients who endorsed use of cannabis for only medical reasons preferred high CBD or similar ratios of THC:CBD products, whereas those endorsing use of both medical and recreational purposes were more likely to use high THC products. Further, patients with chronic pain endorsing both medical and recreational use were more likely to prefer smoking cannabis, versus patients who endorsed only medical use who preferred vaporising. Our findings were consistent across bodies of evidence (quantitative, qualitative and mixed-method studies). The certainty of evidence for most findings was moderate, predominantly due to risk of bias or imprecision/adequacy.

We asked three patient partners on the BMJ rapid recommendation panel for their comments on the findings of this systematic review. In particular, (1) whether our findings reflected their experiences, and (2) if some of the findings were different from their experience, what were possible reasons? The patient partners agreed that all except one of our review findings (table 2) reflected their experiences with cannabis. Specifically, they suggested that patients who are using medical cannabis may not receive support from family or friends due to stigma and misinformation about cannabis use.

Our findings that some patients select medical cannabis based on properties that dispensers attributed to strain type (indica or sativa), represents an opportunity for education. When these strains were originally characterised, sativa was shown to produce higher amounts of CBD whereas indica strains of cannabis produced high levels of THC. At present, however, commercially available cannabis plants and products have been extensively interbred to produce a multitude of unique strains. As such, the only reliable way to determine the composition of any form of medical cannabis is through accurate reporting of the cannabinoid (eg, THC, CBD) content.

We found important differences between patients who use cannabis for medical reasons only and those who report combined use (medical and recreational) in preferences regarding cannabis content and route of administration. Observational studies have shown that most consumers of cannabis endorse medical and recreational use, which presents a challenge to therapeutic use. Recreational users often prioritise cannabis with high THC concentrations, a psychotropic cannabinoid that is associated with greater harms than CBD. Patients who use cannabis for both medical and recreational purposes are also more likely to prefer inhaled forms of administration, which has a much faster onset and greater bioavailability than ingestion but also entails pulmonary risk factors due to inhalation of toxins and particulate matter. Therapeutic use of cannabis should prioritise formulations supported by evidence, administered in a manner that prioritises both safety and effectiveness.
Implications
Our findings have direct implications for clinicians attending people living with chronic pain who are considering use of medical cannabis. Benefits (effect on pain and reduction of prescription medications), harms (adverse effects), burdens (negative social consequences, cost) and accessibility (including legal status) of medical cannabis all appear to influence patients’ decisions related to use. However, we did not identify any studies that considered how patients prioritised these factors. Subsequent research should address this issue. In addition, how patient characteristics (eg, medical conditions, social economic status, religious beliefs) affect their values and preferences is another issue worth addressing in subsequent research.

CONCLUSIONS
There exists high variability of values and preferences towards medical cannabis among people living with chronic pain, particularly related to their willingness to use medical cannabis. These findings suggest that an individualised patient-centred approach, such as shared decision making, should be emphasised for empowering patients to make choices that best suit their own values and preferences and accommodate their context.

REFERENCES


40 Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 2015;110:19–35.

Appendix 1 Search strategies and results in MEDLINE, Embase and PsycInfo
March 17, 2020
MEDLINE
Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present
Search Strategy:
--------------------------------------------------------------------------------
1 Cannabis/ (8934)
2 exp cannabinoids/ or cannabidiol/ or cannabinol/ or dronabinol/ (13763)
3 Endocannabinoids/ (5620)
4 exp Receptors, Cannabinoid/ (9222)
5 (Cannabis or cannabinol or cannabinoid* or cannabidiol or bhang or cannador or charas or ganja or ganjah or hashish or hemp or marihuana or marijuana or nabilone or cesamet or cesametic or ajulemic acid or cannabichromene or cannabielsoin or cannabigerol or tetrahydrocannabinol or dronabinol or levonantradol or nabiximols or palmidrol or tetrahydrocannabinolic acid or tetrahydro cannabinoil or marino or tetrabinex or sativex or endocannabinoid*).mp. (54746)
6 or/1-5 (54746)
7 "marijuana use"/ or marijuana smoking/ (5304)
8 Marijuana Abuse/ (6168)
9 (epidiolex or gwp 42003p or gwp42003p or nabidiolex or dronabinol or thc or tetrahydrocannabinol* or ea 1477 or ea1477 or marinol or qcd 84924 or syndros or tetrabinex or tetrabinex or cesamet or nabilone or daltanyne or "abott 40566" or naminol or dronabinolom or "QCD 84924" or "CCRIS 4726" or nabiximol* or "gw 1000" or gw1000 or "sab 378" or sab378 or sativex).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (11622)
10 or/1-9 (54746)
11 or/1-10 (55952)
12 *Attitude to Health/ (42364)
13 *Patient Participation/ (14355)
14 *Patient Preference/ (5009)
15 preference*.ti,ab. (148469)
16 choice.ti. (31408)
17 choices.ti. (6250)
18 value.ti. (124160)
19 health state values.ti,ab. (175)
20 valuation*.ti. (1523)
21 expectation*,ti,ab. (85695)
22 attitude*,ti,ab. (144860)
23 acceptab*,ti,ab. (174183)
24 knowledge,ti,ab. (676935)
25 point of view,ti,ab. (41412)
26 user participation,ti,ab. (243)
27 users participation,ti,ab. (49)
28 patient participation,ti,ab. (2134)
29 patients participation,ti,ab. (589)
30 patient perspective*,ti,ab. (3526)
31 patients perspective*,ti,ab. (5820)
32 user perspective*,ti,ab. (466)
33 users perspective*,ti,ab. (513)
34 patient perce*,ti,ab. (5165)
35 patients perce*,ti,ab. (9776)
36 health perception*,ti,ab. (2652)
37 user perce*,ti,ab. (351)
38 users perce*,ti,ab. (786)
39 user view*,ti,ab. (110)
40 users view*,ti,ab. (369)
41 patient view*,ti,ab. (546)
42 patients view*,ti,ab. (2807)
43 (decision* and mak*).ti, or (decision mak* or decisions mak*).ti,ab.) and (patient* or user* or men or women).ti,ab. (73905)
44 discrete choice*,ti,ab. (1942)
45 decision board*,ti,ab. (45)
46 decision analy*,ti,ab. (7477)
47 decision-support,ti,ab. (13930)
48 decision tool*,ti,ab. (808)
49 decision aid*,ti,ab. (2976)
50 discrete-choice*,ti,ab. (1942)
51 *Decision Making/ and (patient* or user* or men or women).ti. (5869)
52 decision support techniques/ (19921)
(health and utilit*).ti. (1434)
gamble*.ti,ab. (4395)
prospect theory,ti,ab. (285)
preference score,ti,ab. (163)
preference elicitation,ti,ab. (179)
health utilit*,ti,ab. (2017)
utility value*,ti,ab. (1487)
utility score*,ti,ab. (1378)
Utility estimate*,ti,ab. (269)
health state,ti,ab. (4119)
feeling thermometer*,ti,ab. (68)
best-worst scaling,ti,ab. (202)
standard gamble,ti,ab. (832)
time trade-off,ti,ab. (1150)
TTO,ti,ab. (1026)
probability trade-off,ti,ab. (20)
utility score,ti,ab. (507)
preference based,ti,ab. (1291)
preference score*,ti,ab. (495)
multiattribute,ti,ab. (337)
multi attribute,ti,ab. (523)
EuroQol 5D,ti,ab. (1268)
EuroQol5D,ti,ab. (19)
EQ5D,ti,ab. (550)
EQ 5D,ti,ab. (7695)
SF6D,ti,ab. (32)
SF 6D,ti,ab. (753)
HUI,ti,ab. (1169)
15D,ti,ab. (1704)
or/12-81 (1494263)
(patient adj3 (value* or preference*)).ti,ab. (16093)
(patient* adj5 (report* or relate*) adj5 (outcome* or measure* or assess*)).mp. (41519)
patient participation/ or doctor patient relation/ or nurse patient relationship/ or patient attitude/ or patient preference/ or patient satisfaction/ or patient compliance/ or medication compliance/ or patient decision making/ or patient education/ or chronic patient/ or attitude to health/ or *"quality of life"*/ or self care/ or self concept/ or self examination/ or adaptive behavior/ or coping behavior/ or coping.ab,ti. or needs assessment/ or personal autonomy/ or patient advocacy/ or life event/ (688791)

(patient* adj3 (prefer* or participat* or involve* or perspective* or view* or activat* or empower* or collaborate)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (154936)

(patient* adj2 (attitude* or decision* or needs*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (32381)

expert patient*.mp. (261)

(patient* and (centre* or center* or focus*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (726322)

patien*.mp. and (decision making/ or medical decision making/ or cooperation/ or distress syndrome/ or emotional stress/) [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (44808)

or/83-90 (1481530)

82 or 91 (2686916)

11 and 92 (6739)

(chronic adj4 pain*).mp. (68992)

Chronic Pain/ (13719)

exp Osteoarthritis/ (61921)

osteoarthrit*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (474)

exp Arthritis, Rheumatoid/ (111604)

exp Neuralgia/ (20041)

Diabetic Neuropathies/ (14472)

(neuropath* adj5 pain*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (24189)
neuralg*.mp. (26998)
zoster.mp. (20810)
Irritable Bowel Syndrome/ (7099)
IBS.mp. (8807)
Migraine Disorders/ (24884)
migraine*.mp. (38930)
Fibromyalgia/ (8287)
Fibromyalg*.mp. (11565)
complex regional pain syndromes/ or causalgia/ or reflex sympathetic dystrophy/ (5486)
Pain, Intractable/ (6166)
Phantom Limb/ (1855)
Hyperalgesia/ (11498)
exp back pain/ or failed back surgery syndrome/ or low back pain/ (38351)
radiculopath*.mp. (9283)
Musculoskeletal Pain/ (3090)
Headache/ (27380)
exp Headache Disorders/ (33884)
headache*.mp. (92254)
exp Temporomandibular Joint Disorders/ (17098)
whiplash.mp. (3942)
Whiplash Injuries/ (3216)
ex Cumulative Trauma Disorders/ (13612)
ex Peripheral Nervous System Diseases/dt, rh, th [Drug Therapy, Rehabilitation, Therapy] (29519)
Pain Measurement/de [Drug Effects] (6646)
(backache* or backpain* or dorsalgi* or arthralgi* or polyarthralgi* or arthrodyni* or myalgi* or fibromyalgi* or myodyni* or neuralgi* or ischialgi* or crps or rachialgi*).ti,ab. (44403)
((noncancer* or non-cancer* or back or discogen* or chronic* or recurrent or persist* or bone or musculoskeletal* or muscle* or skeletal* or spinal or spine or vertebra* or joint* or arthritis or Intestin* or neuropath* or neck or cervical* or head or facial* or complex or radicular or cervicobrachi* or orofacial or somatic or non-malign* or shoulder* or knee* or hip or hips) adj3 pain).mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (215471)
or/94-128 (633956)
Annotation: chronic pain and painful conditions
130 93 and 129 (343)

Embase
Database: Embase <1974 to 2020 March 16>
Search Strategy:
--------------------------------------------------------------------------------
1 cannabis/ (33753)
2 exp cannabinoid/ (65425)
3 medical cannabis/ (2094)
4 exp cannabinoid receptor/ (14516)
5 exp endocannabinoid/ (8544)
6 (Cannabis or cannabinol or cannabinoid* or cannabidiol or bhang or cannador or charas or ganja or ganjah or hashish or hemp or marihuana or marijuana or nabilone or cesamet or cesametic or ajulemic acid or cannabinichromene or cannabielsoin or cannabigerol or tetrahydrocannabinol or dronabinol or levonantradol or nabilomis or palmidrol or tetrahydrocannabinolic acid or tetrahydro cannabinol or maroil or tetranabinex or sativex or endocannabinoid*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (86218)
7 cannabis addiction/ (9661)
8 "cannabis use"/ or cannabis smoking/ (11097)
9 (epidiolex or gwp 42003p or gwp42003p or nabilone or dronabinol or thc or tetrahydrocannabinol* or ea 1477 or ea1477 or maroil or qcd 84924 or syndros or tetrahydrocannabinol or cesamet or nabilone or deltanyne or "abbott 40566" or namisol or dronabinolum or "QCD 84924" or "CCRIS 4726" or nabilomis or "gw 1000" or gw1000 or "sab 378" or sab378 or sativex).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (19601)
10 or/1-9 (89571)
11 *attitude to health/ (55489)
12 *patient participation/ (9554)
13 *patient preference/ (4523)
14 preference*.ti,ab. (180987)
15 choice.ti. (36120)
16 choices.ti. (7375)
17 value.ti. (137715)
18 health state values.ti,ab. (233)
19 valuation*.ti. (2249)
20 expectation*.ti,ab. (106912)
21 attitude*.ti,ab. (179875)
22 acceptab*.ti,ab. (240808)
23 knowledge.ti,ab. (851427)
24 point of view.ti,ab. (57170)
25 user participation.ti,ab. (284)
26 users participation.ti,ab. (52)
27 patient participation.ti,ab. (2881)
28 patients participation.ti,ab. (830)
29 patient perspective*.ti,ab. (5558)
30 patients perspective*.ti,ab. (8635)
31 user perspective*.ti,ab. (564)
32 users perspective*.ti,ab. (624)
33 patient perce*.ti,ab. (8096)
34 patients perce*.ti,ab. (14350)
35 health perception*.ti,ab. (3709)
36 user perce*.ti,ab. (400)
37 users perce*.ti,ab. (902)
38 user view*.ti,ab. (169)
39 users view*.ti,ab. (469)
40 patient view*.ti,ab. (865)
41 patients view*.ti,ab. (3932)
42 (decision* and mak*).ti, or (decision mak* or decisions mak*).ti,ab.) and (patient* or user* or men or women).ti,ab. (111434)
43 discrete choice*.ti,ab. (2789)
44 decision board*.ti,ab. (59)
45 decision analy*.ti,ab. (10602)
46 decision-support.ti,ab. (18317)
47 decision tool*.ti,ab. (1271)
48 decision aid*.ti,ab. (4097)
49 discrete-choice*.ti,ab. (2789)
50 *Decision Making/ and (patient* or user* or men or women).ti. (5671)
(health and utilit*).ti. (2083)
gamble*.ti,ab. (5213)
prospect theory.ti,ab. (286)
preference score.ti,ab. (241)
preference elicitation.ti,ab. (261)
health utilit*.ti,ab. (3331)
utility value*.ti,ab. (2815)
utility score*.ti,ab. (2530)
Utility estimate*.ti,ab. (494)
health state.ti,ab. (6770)
feeling thermometer*.ti,ab. (86)
best-worst scaling.ti,ab. (306)
standard gamble.ti,ab. (1081)
time trade-off.ti,ab. (1674)
TTO.ti,ab. (1635)
probability trade-off.ti,ab. (24)
utility score.ti,ab. (1024)
preference based.ti,ab. (1839)
preference score*.ti,ab. (654)
multiattribute.ti,ab. (376)
multi attribute.ti,ab. (721)
EuroQol 5D.ti,ab. (2064)
EuroQol5D.ti,ab. (39)
EQLS.ti,ab. (1812)
EQ 5D.ti,ab. (14809)
SF6D.ti,ab. (110)
SF 6D.ti,ab. (1370)
HUI.ti,ab. (1774)
15D.ti,ab. (2541)
decision support system/ (21812)
or/11-80 (1879990)
(patient adj3 (value* or preference*)),ti,ab. (25871)
(patient* adj5 (report* or relate*) adj5 (outcome* or measure* or assess*)).mp. (73476)
patient participation/ or doctor patient relation/ or nurse patient relationship/ or patient attitude/ or patient preference/ or patient satisfaction/ or patient compliance/ or medication compliance/ or patient decision making/ or patient education/ or chronic patient/ or attitude to health/ or *"quality of life"/ or self care/ or self concept/ or self examination/ or adaptive behavior/ or coping behavior/ or coping.ab,ti. or needs assessment/ or personal autonomy/ or patient advocacy/ or life event/ (1037242)
(patient* adj3 (prefer* or participat* or involve* or perspective* or view* or activat* or empower* or collaborate)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (234656)
(patient* adj2 (attitude* or decision* or needs*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (119435)
expert patient*.mp. (478)
(patient* and (centre* or center* or focus*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (1258089)
patient decision making/ (9864)
(patient*.mp. and (decision making/ or medical decision making/ or cooperation/ or distress syndrome/ or emotional stress/)) [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (180387)
or/82-90 (2444470)
81 or 91 (3858388)
10 and 92 (13785)
(chronic adj4 pain*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (113744)
chronic pain/ (59665)
exp osteoarthrit*/ (124667)
osteoarthrit*.mp. (138729)
oste-o-arthrit*.mp. (511)
degenerative arthrit*.mp. (1541)
exp rheumatoid arthritis/ (196173)
exp neuralgia/ (102320)
diabetic neuropathy/ (23303)
(neuropath* adj5 (pain or diabet*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (72882)
neuralg*.mp. (29911)
zoster.mp. (37512)  
irritable colon/ (25493)  
(irritable bowel syndrome or IBS).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (24789)  
exp migraine/ (62395)  
migrain*.mp. (69650)  
fibromyalgia/ (19936)  
fibromyalg*.mp. (21561)  
reflex sympathetic dystrophy.mp. (2353)  
complex regional pain syndrome.mp. (7426)  
causalgia.mp. (1039)  
intractable pain/ (4766)  
phantom limb/ or phantom pain/ (2434)  
agnosia/ (3053)  
amputation stump/ (2062)  
exp hyperalgesia/ (20518)  
((noncancer* or non-cancer* or chronic* or recurrent or persist* or non-malign*) adj3 pain).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (130063)  
exp backache/ (106576)  
radiculopathy/ or radiculopath*.mp. (13603)  
exp bone pain/ (17842)  
exp musculoskeletal pain/ (145426)  
arthralgia/ (59500)  
headache*.mp. (271974)  
exp "headache and facial pain"/ (296382)  
temporomandibular joint disorder/ (13611)  
((TMJ or TMJD) and pain*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word] (3753)  
whiplash.mp. or whiplash injury/ (4884)  
exp cumulative trauma disorder/ (20498)  
or/94-131 (1089097)  
93 and 132 (1409)
PsycInfo
Database: APA Psycinfo <1806 to March Week 2 2020>
Search Strategy:
--------------------------------------------------------------------------------
1  exp cannabis/ or exp cannabinoids/ or tetrahydrocannabinol/ (12784)
2  (Cannabis or cannabinol or cannabinoid* or cannabidiol or bhang or canndor or charas or ganja or ganjah or hashish or hemp or marihuana or marijuana or nabilone or cesamet or cesametic or ajulemic acid or cannabinichromene or cannabinolsoin or cannabigerol or tetrahydrocannabinol or dronabinol or levonantradol or nabiximols or palmidrol or tetrahydrocannabinolic acid or tetrahydrocannabinol or marinol or tetranabinex or sativex or endocannabinoid*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (26408)
3  marijuana laws/ or marijuana legalization/ or "cannabis use disorder"/ or marijuana usage/ (3594)
4  (epidiolex or gwp 42003p or gwp42003p or nabidiolex or dronabinol or thc or tetrahydrocannabinol* or ea 1477 or ea1477 or marinol or qcd 84924 or syndros or tetrabinex or tetrabainex or cesamet or nabilone or deltanyne or "abbott 40566" or namisol or dronabinolum or "QCD 84924" or "CCRIS 4726" or nabiximol? or "gw 1000" or gw1000 or "sab 378" or sab378 or sativex).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (3193)
5  or/1-4 (26475)
6  *health attitudes/ (8084)
7  *client participation/ (1678)
8  exp *client attitudes/ (17349)
9  preference*.ti,ab. (95876)
10  choice.ti. (21402)
11  choices.ti. (4602)
12  value.ti. (18077)
13  health state values.ti,ab. (77)
14  valuation*.ti. (983)
15  expectation*.ti,ab. (80049)
16  attitude*.ti,ab. (201050)
17  acceptab*.ti,ab. (38902)
18  knowledge.ti,ab. (290890)
19  point of view.ti,ab. (20482)
20  user participation.ti,ab. (282)
21  users participation.ti,ab. (46)
patient participation.ti,ab. (788)
patients participation.ti,ab. (264)
patient perspective*.ti,ab. (1752)
users perspective*.ti,ab. (345)
patient perce*.ti,ab. (1343)
patients perce*.ti,ab. (3398)
health perception*.ti,ab. (1230)
user perce*.ti,ab. (393)
users perce*.ti,ab. (888)
user view*.ti,ab. (95)
users view*.ti,ab. (289)
patient view*.ti,ab. (210)
patients view*.ti,ab. (1022)
(decision* and mak*).ti,ab or (decision mak* or decisions mak*).ti,ab) and (patient* or user* or men or women).ti,ab. (21062)
discrete choice*.ti,ab. (960)
decision board*.ti,ab. (16)
decision analy*.ti,ab. (1133)
decision-support.ti,ab. (3235)
decision tool*.ti,ab. (169)
decision aid*.ti,ab. (1252)
discrete-choice*.ti,ab. (960)
*Decision Making/ and (patient* or user* or men or women).ti. (3428)
(health and utilit*).ti. (467)
gamble*.ti,ab. (5406)
prospect theory.ti,ab. (964)
preference score.ti,ab. (93)
preference elicitation.ti,ab. (134)
health utilit*.ti,ab. (532)
utility value*.ti,ab. (490)
utility score*.ti,ab. (334)
Utility estimate*.ti,ab. (103)
health state.ti,ab. (958)
feeling thermometer*.ti,ab. (58)
best-worst scaling.ti,ab. (109)
standard gamble.ti,ab. (210)
time trade-off.ti,ab. (279)
TTO.ti,ab. (190)
probability trade-off.ti,ab. (5)
utility score.ti,ab. (101)
preference based.ti,ab. (648)
preference score*.ti,ab. (402)
multiattribute.ti,ab. (531)
multi attribute.ti,ab. (567)
EuroQol 5D.ti,ab. (206)
EuroQol5D.ti,ab. (0)
EQ5D.ti,ab. (61)
EQ 5D.ti,ab. (1677)
SF6D.ti,ab. (10)
SF 6D.ti,ab. (284)
HUI.ti,ab. (445)
15D.ti,ab. (170)
decision support systems/ (3245)
or/6-75 (744950)
client attitudes/ or client satisfaction/ (21785)
values/ or personal values/ or social values/ (22591)
(patient* adj3 (prefer* or participat* or involve* or perspective* or view* or activat* or empower* or collaborate)).mp. (27273)
(patient* adj2 (attitude* or decision* or needs*)).mp. (23750)
or/77-80 (85433)
76 or 81 (783705)
5 and 82 (3282)
chronic pain/ (13151)
chronic illness/ and pain.mp. (916)
back pain/ (3813)
+(chronic* or persist* or refractor* or intract* or manag* or back) adj3 pain).mp. (34808)
or/84-87 (35275)
+exp arthritis/ (4140)
+oste oa rthritis*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (2121)
+exp degenerative arthritis*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (9)
+exp Neuralgia/ (931)
+nergalg*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (3310)
+exp Neuropathy/ (6243)
+exp neuropath* adj5 (pain or diabet*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (6749)
+exp neuroalgalg*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (3310)
+exp zoster.mp. (577)
+IBS or irritable colon or irritable bowel).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (2001)
+exp headache/ (15176)
+exp fibromyalgia/ (1972)
+exp fibromyalg*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (3408)
+exp "complex regional pain syndrome (type i)"/ (152)
+exp (complex regional pain syndrome* or causalgia).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (821)
+exp somatosensory disorders/ (1367)
+exp hyperalgesi*.mp. (5320)
+exp Somatoform Disorders/ (15194)
+(noncancer* or non-cancer* or chronic* or recurrent or persist* or non-malign*) adj3 pain).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (23779)
+exp radiculopath*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (351)
+(back or musculoskeletal) adj3 pain*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (7604)
+exp arthralgia.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (317)
+exp headache*.mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (22401)
+(backache* or backpain or dorsalgi* or arthralgi* or polyarthralgi* or arthrodyn* or myalg* or fibromyalg* or myodny* or neuralg* or ischialg* or crps or
rachialgi*).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (8315)
116 (back or discogen* or bone or musculoskelet* or muscle* or skelet* or spinal or spine or vertebra* or joint* or arthrit* or intestin* or neuropath* or neck or cervical* or head or facial* or complex or radicular or cervicobrach* or orofacial or somatic or shoulder* or knee* or hip or hips*) adj3 pain).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures, mesh] (20949)
117 or/84-116 (93580)
118 83 and 117 (86)
119 5 and 82 and 117 (86)
## Appendix 2 Data extraction form

<table>
<thead>
<tr>
<th>Researcher identification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surname, name</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study identification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study ID</td>
</tr>
<tr>
<td>Country</td>
</tr>
<tr>
<td>Funding</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study objectives or research questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study population</td>
</tr>
<tr>
<td>Description of patients</td>
</tr>
<tr>
<td>Response rate/completion rate</td>
</tr>
<tr>
<td>Male %</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>White %</td>
</tr>
<tr>
<td>Chronic pain %</td>
</tr>
<tr>
<td>Patients ever used cannabis %</td>
</tr>
<tr>
<td>Opioids use %</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aim intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design and methods</td>
</tr>
<tr>
<td>Study design</td>
</tr>
<tr>
<td>Sampling</td>
</tr>
<tr>
<td>Sample size</td>
</tr>
<tr>
<td>Data collection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main findings (themes)</td>
</tr>
<tr>
<td>1. Values and preferences of outcome of medical cannabis</td>
</tr>
<tr>
<td>1.1 Relative value or importance patients put on outcomes of medical cannabis;</td>
</tr>
<tr>
<td>1.2 Tradeoff between benefits and harms or burdens of medical cannabis</td>
</tr>
<tr>
<td>2. Values and preferences towards medical cannabis</td>
</tr>
<tr>
<td>2.1 Values and preference for or against medical cannabis or choosing cannabis over</td>
</tr>
</tbody>
</table>
other medicines

<table>
<thead>
<tr>
<th>2.2 Values and preferences of different preparations of medical cannabis (e.g. administration routes, ingestion method, ratio of THC to CBD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Factors that influence the decision making regarding medical cannabis use</td>
</tr>
<tr>
<td>3.1 Factors that influence use or not use of medical cannabis</td>
</tr>
<tr>
<td>3.2 Factors that influence the choice of medical cannabis over other meds for pain management</td>
</tr>
<tr>
<td>3.3 Factors that influence the choice of different preparations of medical cannabis</td>
</tr>
</tbody>
</table>

Authors’ interpretation

Authors’ conclusions
### Appendix 3 Tool and instructions for risk of bias assessment for quantitative studies

<table>
<thead>
<tr>
<th>Domains</th>
<th>Questions</th>
<th>Instructions for questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participant selection</td>
<td>Was the study sample selected in a manner to ensure the representativeness to the target population?</td>
<td>The sampling strategy solely does not determine the risk of bias; if there is a subset of the population more or less likely to be reached, the answer for “was the study sample selected in a manner to ensure the representativeness” is</td>
</tr>
<tr>
<td>Completeness of data</td>
<td>Was the attrition sufficiently low to minimize the risk of bias?</td>
<td>Response rate for 80% or higher would be considered high for a cross-sectional study.</td>
</tr>
<tr>
<td>Choice of measurement instrument</td>
<td>Was the choice of the methodology appropriate for addressing the study aim?</td>
<td>Consider yes or probably yes for the following methodologies: standard gamble, time trade off, visual analogue scale (or feeling thermometers), discrete choice,</td>
</tr>
<tr>
<td>Administration of measurement instrument</td>
<td>Was the instrument (or tools that was used to elicit values and preferences, e.g. questionnaire) administered in the intended way?</td>
<td>-</td>
</tr>
<tr>
<td>Outcome/health state presentation</td>
<td>Was a valid representation of the outcome/health state (e.g. a state of pain relief - a beneficial outcome of medical cannabis, or an experience of coughing - a harmful outcome of medical cannabis) utilized?</td>
<td>If the researchers demonstrated they were using available evidence to support the health state presentation, the answer should be yes or probably yes.</td>
</tr>
<tr>
<td>Participants’ understanding of the measurement instrument</td>
<td>Did the researchers check the understanding to the measurement techniques (e.g. questionnaire in a survey)?</td>
<td>If the methodology is simple, choosing “the investigators did not formally test the understanding, but the results suggested it was adequate”</td>
</tr>
<tr>
<td>Data analysis</td>
<td>Were the results analyzed appropriately?</td>
<td>To answer this question, reviewers also need to consider whether the adjustment, stratification, or model selection was appropriate.</td>
</tr>
<tr>
<td>Overall risk of bias</td>
<td></td>
<td>- Low risk of bias= The study is classified as with low risk of bias across subdomains.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Moderate risk of bias= The study is classified as low (Yes -&gt; low risk of bias) or moderate (Probably yes -&gt; moderate risk</td>
</tr>
</tbody>
</table>

**Notes:**
- BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
<table>
<thead>
<tr>
<th>Years of experience</th>
<th>0-4</th>
<th>5-9</th>
<th>10 or more</th>
</tr>
</thead>
<tbody>
<tr>
<td>Years of study</td>
<td>0-1</td>
<td>2-3</td>
<td>4 or more</td>
</tr>
<tr>
<td>Language proficiency</td>
<td>English</td>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>Research methods</td>
<td>Qualitative</td>
<td>Quantitative</td>
<td></td>
</tr>
<tr>
<td>Funding source</td>
<td>Academic</td>
<td>Industry</td>
<td></td>
</tr>
<tr>
<td>Study design</td>
<td>Field randomized</td>
<td>Blinded</td>
<td></td>
</tr>
</tbody>
</table>

This domain may not be applicable to all primary studies because not all studies will require controlled data analysis. Please check "NA" if not applicable.

• Serious risk of bias= The study is classified as serious risk of bias (Probably no -> serious risk of bias) for at least one subdomain but not classified as critical risk of bias for any subdomain.

• Critical risk of bias= The study is classified as critical risk of bias (No -> critical risk of bias) for at least one subdomain.
### Appendix 4 Tool and instructions for methodological limitation assessments for qualitative studies

<table>
<thead>
<tr>
<th>Domains</th>
<th>Questions</th>
<th>Instructions for questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aim of the research</td>
<td>Was there a clear statement of the aims of the research?</td>
<td>• If the researcher sought to interpret or illuminate the actions and/or subjective experiences of research participants</td>
</tr>
<tr>
<td>Qualitative methodology</td>
<td>Is a qualitative methodology appropriate?</td>
<td>• What was the goal of the research?</td>
</tr>
<tr>
<td>Appropriateness</td>
<td>Was the research design appropriate to address the aims of the research?</td>
<td>• Why it was thought important?</td>
</tr>
<tr>
<td>Recruitment strategy</td>
<td>Was the recruitment strategy appropriate to the aims of the research?</td>
<td>• Its relevance</td>
</tr>
<tr>
<td>Data collection</td>
<td>Was the data collected in a way that addressed the research issue?</td>
<td>• Is qualitative research the right methodology for addressing the research goal?</td>
</tr>
<tr>
<td>Investigator-participant</td>
<td>Has the relationship between researcher and participants been adequately considered?</td>
<td>• If the researcher decided which method to use.</td>
</tr>
<tr>
<td>relationship</td>
<td>Have ethical issues been taken into consideration?</td>
<td>• If the researchers selected the participants they thought were the most appropriate to provide</td>
</tr>
<tr>
<td>Ethical issues</td>
<td>Was the data analysis sufficiently rigorous?</td>
<td>• If the researcher explained how the setting for the data collection was justified.</td>
</tr>
<tr>
<td>Data analysis</td>
<td>Was there a clear statement of the findings?</td>
<td>• If the researcher critically examined their own role, potential bias and influence during (a) formulation of the research questions (b) data collection, including sample.</td>
</tr>
<tr>
<td>Findings</td>
<td>Is there a value of the research?</td>
<td>• If there are sufficient details of how the research was explained to participants for the reader to assess whether ethical standards were maintained.</td>
</tr>
<tr>
<td>Value of the research</td>
<td>How valuable is the research?</td>
<td>• If there is an in-depth description of the analysis process.</td>
</tr>
<tr>
<td>Overall methodological</td>
<td>How are the limitations presented?</td>
<td>• If the findings are explicit.</td>
</tr>
<tr>
<td>limitations</td>
<td></td>
<td>• If the researcher discusses the contribution the study makes to existing knowledge or understanding (e.g. do they consider the findings in relation to current practice or policy, or relevant research-based literature).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Minor = if more than 2 questions had &quot;No&quot;.</td>
</tr>
<tr>
<td>• Moderate = if 2 questions had &quot;No&quot;.</td>
</tr>
<tr>
<td>• No or minor = if less than 2 questions had &quot;No&quot;.</td>
</tr>
</tbody>
</table>
access to the type of knowledge sought by the study

- If there are any discussions around recruitment (e.g. why some people chose not to take part)
- If the researcher has made the methods explicit
- If methods were modified during the study, if so, has the researcher explained how and why
- If the form of data is clear
- If the researcher has discussed saturation of data

recruitment and choice of location
- How the researcher responded to events during the study and whether they considered the implications of any changes in the research design
- If approval has been sought from the ethics committee
- If the researcher explained new areas where research is necessary

were selected from the original sample to demonstrate the analysis process
- If sufficient data are presented to support the findings
- To what extent contradictory data are taken into account
- Whether the researcher critically examined their own role, potential bias and influence during analysis and selection of data for presentation

If the researcher has discussed the credibility of their findings
- If the findings are discussed in relation to the original research question
- If the researchers have discussed whether or how the findings can be transferred to other populations or considered other ways the research may be used
### Appendix 5 Characteristics of the included studies

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Country</th>
<th>Funding sources</th>
<th>Primary focus</th>
<th>Study design</th>
<th>Data collection methods</th>
<th>Sampling</th>
<th>Participants, n</th>
<th>Male Sex, %</th>
<th>Chronic pain, %</th>
<th>Chronic cancer pain, %</th>
<th>Prior use of cannabis, %</th>
<th>Risk of Bias/Methodological Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bigand</td>
<td>United States</td>
<td>Non-industry funding</td>
<td>To examine the perceived effects of medical cannabis among patients who are prescribed opioids for persistent pain conditions</td>
<td>Qualitative, Descriptive</td>
<td>Questionnaire</td>
<td>Convenience</td>
<td>150</td>
<td>31.3</td>
<td>100</td>
<td>NR</td>
<td>69.3</td>
<td>Serious</td>
</tr>
<tr>
<td>Boehnke</td>
<td>United States</td>
<td>NR</td>
<td>To assess preferences towards medical cannabis products among medical cannabis users with chronic pain</td>
<td>Quantitative, Cross-sectional</td>
<td>Questionnaire</td>
<td>Convenience</td>
<td>1321</td>
<td>40.9</td>
<td>NR</td>
<td>100</td>
<td>100</td>
<td>Moderate</td>
</tr>
<tr>
<td>Bruce</td>
<td>United States</td>
<td>Non-industry funding</td>
<td>To assess approaches to medical cannabis use vis-a-vis prescription medications among patients with chronic conditions</td>
<td>Qualitative, Descriptive</td>
<td>Semi-structured telephone interviews</td>
<td>Convenience</td>
<td>30</td>
<td>60.3</td>
<td>NR</td>
<td>100</td>
<td>100</td>
<td>No or minor</td>
</tr>
<tr>
<td>Cooke</td>
<td>United States</td>
<td>Non-industry funding</td>
<td>To explore perspectives on the co-use of medical cannabis and opioids among clinicians, and</td>
<td>Qualitative, Modified grounded theory</td>
<td>Semi-structured in-person interviews</td>
<td>Purposive</td>
<td>46</td>
<td>45.6</td>
<td>100</td>
<td>0</td>
<td>45.7</td>
<td>Moderate</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Funding</td>
<td>Objective</td>
<td>Study Design</td>
<td>Sample Size</td>
<td>Mean Age</td>
<td>Gender</td>
<td>Methodology</td>
<td>Score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>-----------</td>
<td>------------------------</td>
<td>----------------------------------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>-------------</td>
<td>----------</td>
<td>--------</td>
<td>-------------</td>
<td>--------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Degenhardt 2015</td>
<td>Australia</td>
<td>Non-industry funding</td>
<td>To investigate patterns and correlates of medical cannabis use among patients who are prescribed opioids for chronic non-cancer pain</td>
<td>Quantitative, Cross-sectional, Questionnaire, and diagnostic interview</td>
<td>1514</td>
<td>44.4</td>
<td>100</td>
<td>0</td>
<td>43</td>
<td>Moderate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gallagher 2003</td>
<td>Canada</td>
<td>NR</td>
<td>To survey willingness to try medical cannabis among patients with a known advanced life-limiting illness, and to assess this population's knowledge about medical cannabis</td>
<td>Quantitative, Cross-sectional</td>
<td>68</td>
<td>44.6</td>
<td>NR</td>
<td>100</td>
<td>35.3</td>
<td>Critical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gill 2001</td>
<td>United Kingdom</td>
<td>NR</td>
<td>To investigate beliefs about cannabinoids and the associations between those beliefs, beliefs about medication, and personal and pain variables in relation to willingness to try cannabinoids as analgesics, among</td>
<td>Quantitative, Cross-sectional, Questionnaire</td>
<td>65</td>
<td>45</td>
<td>100</td>
<td>NR</td>
<td>NR</td>
<td>Serious</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reference</td>
<td>Country</td>
<td>Funding</td>
<td>Objective</td>
<td>Study Design</td>
<td>Sample Size</td>
<td>Withdrawals</td>
<td>Study Quality</td>
<td>Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>---------------</td>
<td>--------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heng 2018</td>
<td>United States</td>
<td>NR</td>
<td>To assess beliefs regarding using marijuana for medicine, post injury pain and speaking about marijuana to their health care providers, among patients who have a musculoskeletal injury in the last 1-6 months.</td>
<td>Quantitative, Cross-sectional</td>
<td>500</td>
<td>50</td>
<td>NR</td>
<td>60</td>
<td>Moderate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lavie-Ajayi 2019</td>
<td>Israel</td>
<td>Non-industry funding</td>
<td>To explore and characterize the experience of using medical cannabis for chronic pain among patients receiving medical cannabis for at least three months.</td>
<td>Qualitative, Phenomenological</td>
<td>19</td>
<td>52.6</td>
<td>100</td>
<td>5.3</td>
<td>100</td>
<td>No or minor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Notcutt 2004</td>
<td>United Kingdom</td>
<td>Non-industry funding</td>
<td>To evaluate the safety and tolerability of three CBMEs among patients with stable chronic pain, and poorly responsive to other modalities.</td>
<td>Quantitative, RCT</td>
<td>NR</td>
<td>34</td>
<td>32</td>
<td>100</td>
<td>NR</td>
<td>Moderate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author</td>
<td>Country</td>
<td>Funding</td>
<td>Objective</td>
<td>Methods</td>
<td>Sample Size</td>
<td>Response Rate</td>
<td>Compliance</td>
<td>Complexity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------</td>
<td>------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-------------</td>
<td>---------------</td>
<td>-------------</td>
<td>--------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Piper 2017</td>
<td>United States</td>
<td>Non-industry</td>
<td>To survey perspectives of medical cannabis among legal members of medical cannabis dispensaries, and to examine the strengths and limitations of medical cannabis</td>
<td>Mixed Methods, Cross-sectional Online survey, discrete choice, open-ended questions</td>
<td>984</td>
<td>47.1</td>
<td>100 §</td>
<td>16.7</td>
<td>100</td>
<td>Serious</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rochford 2019</td>
<td>Ireland</td>
<td>NR</td>
<td>To evaluate attitudes towards medicinal cannabis among patients who attend chronic pain clinics</td>
<td>Quantitative, Cross-sectional Questionnairenaire</td>
<td>96</td>
<td>39.6</td>
<td>100</td>
<td>22.9</td>
<td>NR</td>
<td>Serious</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Satterlund 2015</td>
<td>United States</td>
<td>Non-industry</td>
<td>To assess perceived risk, concern or overall stigma of marijuana use, and how this stigma may affect the health care among medical marijuana users ≤</td>
<td>Qualitative, Descriptive Semi-structured interviews Convenience and snowball</td>
<td>18</td>
<td>72</td>
<td>NR</td>
<td>100</td>
<td>Moderate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sexton 2016</td>
<td>United States</td>
<td>Non-industry</td>
<td>To survey the patterns of use and perceived efficacy of medical cannabis among patients who have used medical cannabis in the last 90 days</td>
<td>Quantitative, Cross-sectional Questionnairenaire</td>
<td>1429</td>
<td>54.6</td>
<td>NR</td>
<td>100</td>
<td>Moderate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zarrabi/Singh 2019</td>
<td>United States</td>
<td>Non-industry</td>
<td>To survey perceptions of the benefits and</td>
<td>Quantitative, Cross-questionnairenaire</td>
<td>101</td>
<td>55.7</td>
<td>100</td>
<td>75.5</td>
<td>100</td>
<td>Serious</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
funding harms of medical cannabis, concerns about access to cannabis, and perceptions of support from family and health care providers, among patients with serious illness in APC

Note:

a Chronic overlapping pain conditions: back pain 58%, migraine 21%, fibromyalgia 15%, irritable bowel disease or Crohn's disease 14%, temporomandibular joint disorder 6%.
b Rheumatoid arthritis 23.3%, spinal cord disease or injury 20%, Chron's disease 20%, cancer 13.3%, hepatitis C 13.3%, post-traumatic stress disorder (PTSD) 13.3%, severe fibromyalgia 10%, other (chronic regional pain syndrome, epilepsy, HIV, MS, Parkinson's) 23.3%.
c Majority (≥80%) were patients with chronic and severe pain.
d Advanced life-limiting illnesses include malignancy, advanced cardiac, respiratory, liver or neurological diseases.
e The mean score of intensity of pain was 4.9 on a 0 to 10 VAS scale (0= absence of pain, 10=the worst pain intensity imaginable).
f Patients had experienced a musculoskeletal injury between 1 to 6 months before entry into the study.
g All the participants were legal members of medical cannabis dispensaries in the north-eastern US. Sixty-four percent of patients reported that they had been diagnosed with chronic pain by a medical professional.
h The authors stated "Maladies for which respondents used medical marijuana included migraine headaches, depression, chemotherapy and radiation treatment effects, chronic pain, and asthma, with the majority citing chronic and severe pain".
i Sixty-one percent of patients reported chronic pain, 35.5% had headache/migraine and the remaining 3.5% had other chronic pain conditions.
### Appendix 6 Excluded studies and reasons for exclusion in full text screening

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Aggarwal 2014</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>2. Allan 2018</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>3. Bekker 2018</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>4. Cairns 2017</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>5. Caplan B 2018</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>6. Choo 2016</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>7. Nickel 2018</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>8. Djulus 2005</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>9. Dowden 2019</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>10. Gieringer 2003</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>11. Harrison 2013</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>12. Kepple 2016</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>13. Kinnucan 2018</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>14. Bachhuber 2018</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>15. Zolotov 2016</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>16. Lum 2019</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>17. Martins-Welch 2017</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>18. Naguib 2015</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>19. Page 2015</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>20. Parmar 2016</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>21. Paut Kusturica2019</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>22. Pearce 2014</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>23. Pink 2012</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>24. Piper 2018</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>25. Reid 2013</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>26. Reiman 2008</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>27. Reisfield 2009</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>28. Reynolds 2017</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>29. Reynolds 2018</td>
<td>Not value and preference</td>
</tr>
<tr>
<td>30. Ste-Marie 2015</td>
<td>Not value and preference</td>
</tr>
</tbody>
</table>
63. Wurzen 2018
   Abstract only

64. Grinberg 2018
   Not patients with chronic pain or their carer

65. Iskedjian 2009
   Not patients with chronic pain or their carer

66. Grotenhermen 2003
   Not patients with chronic pain or their carer

67. LAU 2015
   Not patients with chronic pain or their carer

68. Ishida 2019
   Not patients with chronic pain or their carer

69. Lucas 2019
   Not patients with chronic pain or their carer

70. Wan 2017
   Not patients with chronic pain or their carer

71. Mendoza 2016
   Not patients with chronic pain or their carer

72. Mendoza 2018
   Not patients with chronic pain or their carer

73. Schenker 2019
   Not patients with chronic pain or their carer

74. Sharon 2018
   Not patients with chronic pain or their carer

75. St-Amant 2015
   Not patients with chronic pain or their carer

76. Starrels 2018
   Not patients with chronic pain or their carer

77. Starrels 2020
   Not patients with chronic pain or their carer

78. Zolotov 2019
   Not patients with chronic pain or their carer

79. Zolotov 2019
   Not patients with chronic pain or their carer

80. Nouryan 2018
   Not patients with chronic pain or their carer

81. Boehnke 2019
   Not patients with chronic pain or their carer

82. Khelemsky 2017
   Not patients with chronic pain or their carer

83. Vargas-Schaffer 2018
   Not cannabis

84. Manchikanti 2008
   Not cannabis

85. Mijatovic 2019
   Not cannabis

86. Friedberg 2016
   Personal experience

87. Greenberg 2019
   Personal experience

88. Burke 2010
   Value and preference data not elicited from patients or their carers
List of excluded studies at full text screening and reasons for exclusion

1. Not value and preference (n=42)


2. Abstract only (n=21)


3. Not patients with chronic pain or their carer (n=19)


4. Not cannabis (n=3)

5. Personal experience (case study) (n=2)

6. Value and preference data not elicited from patients or their carers (n=1)
### Appendix 7 Risk of bias assessments for quantitative studies

<table>
<thead>
<tr>
<th>Study ID (Reference number)</th>
<th>Was the study sample selected in a manner to ensure the representativeness to the target population?</th>
<th>Was the attrition sufficiently low to minimize the risk of bias?</th>
<th>Was the choice of the methodology appropriate for addressing the study aim?</th>
<th>Was the instrument (or tools that was used to elicit values and preferences, e.g. questionnaire) administered in the intended way?</th>
<th>Was a valid representation of the outcome/health state (e.g. a state of pain relief - a beneficial outcome of medical cannabis, or an experience of coughing - a harmful outcome of medical cannabis) utilized?</th>
<th>Did the researchers check the understanding to the measurement techniques (e.g. questionnaire in a survey)?</th>
<th>Were the results analyzed appropriately?</th>
<th>Overall risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boehnke 2019 (21) Degenhardt 2015 (24)</td>
<td>Probably yes</td>
<td>Probably yes</td>
<td>Probably yes</td>
<td>Yes</td>
<td>NA</td>
<td>Probably yes</td>
<td>Yes</td>
<td>Moderate</td>
</tr>
<tr>
<td>Degenhardt 2015 (24)</td>
<td>Probably yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
<td>Probably yes</td>
<td>Yes</td>
<td>Moderate</td>
</tr>
<tr>
<td>Heng 2018 (27)</td>
<td>Probably yes</td>
<td>Yes</td>
<td>Probably yes</td>
<td>Yes</td>
<td>NA</td>
<td>Probably yes</td>
<td>Yes</td>
<td>Moderate</td>
</tr>
<tr>
<td>Gill 2001 (26)</td>
<td>Probably yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Probably yes</td>
<td>NA</td>
<td>Probably no</td>
<td>Probably yes</td>
<td>Serious</td>
</tr>
<tr>
<td>Gallagher 2003 (25)</td>
<td>Probably yes</td>
<td>Probably no</td>
<td>Yes</td>
<td>Yes</td>
<td>Probably no</td>
<td>Probably no</td>
<td>Probably no</td>
<td>Critical</td>
</tr>
<tr>
<td>Piper BJ 2017 (35)</td>
<td>Yes</td>
<td>Probably no</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>Serious</td>
</tr>
<tr>
<td>Sexton 2016 (30)</td>
<td>Yes</td>
<td>Probably yes</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>Moderate</td>
</tr>
<tr>
<td>Zarrabi 2020, Singh 2019 (31,34)</td>
<td>Probably yes</td>
<td>Probably yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Probably no</td>
<td>Probably no</td>
<td>Yes</td>
<td>Serious</td>
</tr>
<tr>
<td>Notcutt 2004 (33)</td>
<td>Probably yes</td>
<td>Probably Yes</td>
<td>Probably yes</td>
<td>Probably yes</td>
<td>NA</td>
<td>Probably yes</td>
<td>Probably yes</td>
<td>Moderate</td>
</tr>
<tr>
<td>Rochford 2019 (29)</td>
<td>Probably no</td>
<td>Probably yes</td>
<td>Probably yes</td>
<td>Probably yes</td>
<td>NA</td>
<td>Probably yes</td>
<td>Probably yes</td>
<td>Serious</td>
</tr>
</tbody>
</table>
### Appendix 8 Methodological limitations assessments for qualitative studies

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Was there a clear statement of the aims of the research?</th>
<th>Is a qualitative methodology appropriate?</th>
<th>Was the research design appropriate to address the aims of the research?</th>
<th>Was the recruitment strategy appropriate to the aims of the research?</th>
<th>Was the data collected in a way that addressed the research issue?</th>
<th>Has the relationship between researcher and participants been adequately considered?</th>
<th>Have ethical issues been taken into consideration?</th>
<th>Was the data analysis sufficiently rigorous?</th>
<th>Is there a clear statement of findings?</th>
<th>How valuable is the research?</th>
<th>Overall methodological limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruce 2018 (22)</td>
<td>Yes</td>
<td>Yes</td>
<td>Can't tell</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No or minor</td>
<td></td>
</tr>
<tr>
<td>Cooke 2019 (23)</td>
<td>Yes</td>
<td>Yes</td>
<td>Can't tell</td>
<td>Yes</td>
<td>No</td>
<td>Can't tell</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Bigand 2019 (20)</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Can't tell</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Serious</td>
<td></td>
</tr>
<tr>
<td>Lavie-Ajayi 2019 (28)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Can't tell</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No or minor</td>
<td></td>
</tr>
<tr>
<td>Satterlund 2015 (32)</td>
<td>Yes</td>
<td>Yes</td>
<td>Can't tell</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Moderate</td>
<td></td>
</tr>
</tbody>
</table>
### Appendix 9 Evidence profile for review findings

<table>
<thead>
<tr>
<th>Review finding</th>
<th>Explanation</th>
<th>Certainty assessment with GRADE/ GRADE CERQual</th>
<th>Certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Study design (Reference number)</td>
<td>NO. of studies (participants)</td>
</tr>
<tr>
<td>1. Values and preferences towards medical cannabis</td>
<td>[Quantitative] Most patients with advanced life-limiting illnesses were comfortable using cannabis for chronic pain and nausea (25), while other non-palliative patients with chronic pain were unwilling or ambivalent about medical cannabis use (26). Non-White patients with advanced illness were more concerned about medical cannabis compared to White patients, but they remained comfortable using medical cannabis (25). Chronic pain patients who use both medical cannabis and other prescription medications believed that medical cannabis was effective for managing chronic pain (27).</td>
<td>Quantitative (25,26,27)</td>
<td>3 (633)</td>
</tr>
<tr>
<td>1.1 Use of medical cannabis for chronic pain</td>
<td>[Qualitative] Patients with a range of chronic medical conditions believed that medical cannabis was effective for pain (22).</td>
<td>Qualitative (22)</td>
<td>1 (30)</td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on the information supplied by the author(s).
Most patients who use medical cannabis had a positive attitude toward its use for pain relief. Those using medical cannabis during their recovery believed that it reduced pain (25). Most individuals expressed positive aspects of medical cannabis use, such as pain reduction (27, 31, 34). The majority of participants with cancer in one study reported using cannabis products for a “cancer cure” (31). Some believed that cannabis should be legalized for medical purposes (29).

[Qualitative]
Most individuals expressed use of medical cannabis for chronic pain was associated with a range of improved outcomes (e.g. better function, sleep, life changing etc.) (28).

1.2 Medical cannabis over other pain medicines
Patients with chronic pain and substance use histories preferred medical cannabis over prescription opioids.

<table>
<thead>
<tr>
<th>Patients with chronic pain and substance use histories preferred medical cannabis over prescription opioids.</th>
<th>Quantitative (25, 27, 29, 31, 34)</th>
<th>4 (765)</th>
<th>Serious risk</th>
<th>Not serious</th>
<th>Serious</th>
<th>Not serious</th>
<th>Not serious</th>
<th>Low</th>
</tr>
</thead>
</table>

[Qualitative (28) | 1 (19) | No or very minor concerns | NA | No or very minor concerns | Serious concerns | No or very minor concerns | Moderate |

| Qualitative (23) | 1 (46) | No or very minor concerns | NA | Minor concerns | Serious concerns | No or very minor concerns | Low |
Some patients believed that medical cannabis is safer than morphine and other strong pain killers. Some participants believed that because cannabis is a ‘natural’ product, it is safer than morphine and other strong pain killers (25). Non-Christians were more likely to believe that cannabis is safer than morphine (25). Those with high school education or less, were significantly less likely to believe that cannabis was safer than morphine (25).

### 1.3 Different preparations of medical cannabis

**Cannabis variety (i.e. sativa, indica, hybrid)**

<table>
<thead>
<tr>
<th>Preference</th>
<th>Quantitative (21)</th>
<th>1 (1321)</th>
<th>Serious risk</th>
<th>Not serious</th>
<th>Not serious</th>
<th>Not serious</th>
<th>Not serious</th>
<th>Moderate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most patients preferred medical cannabis with a blend of indica and sativa, regardless of gender, reasons for use, and cannabis</td>
<td>Most patients preferred using a blend of indica and sativa to manage chronic pain, followed by indica alone and sativa alone. There were no differences in cannabis variety preferences between males and females, those who use cannabis for medical purposes only and those who use for medical and recreational purposes, or novice and experienced users.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
High THC and high CBD is the most preferred preparation, but gender, reason for use, and cannabis experience level influenced patients' preference for cannabis ratio.

[Quantitative]
Females preferred low THC: high CBD, while males preferred equal ratios of THC: CBD. (21)

Patients who use cannabis for medical purposes reported a greater preference for products with low THC: high CBD compared to individuals who use cannabis both medically and recreationally. (21)

Both novice and experienced cannabis users preferred high CBD products most, and more novice users prefer low THC: high CBD while experienced users preferred high THC: high CBD. (21) Almost none preferred high THC and low CBD, low THC and low CBD, only CBD, or only THC. (21, 33)

Quantitative (21, 33)
2 (1355)
Serious risk
Not serious
Not serious
Not serious
Moderate

**Cannabis administration route**
<table>
<thead>
<tr>
<th>Gender, reason for use and cannabis experience level influenced patients' preferred cannabis administration routes.</th>
<th>Quantitative (21), Mixed (35)</th>
<th>Quantitative (21), 2 (2305)</th>
<th>Serious risk</th>
<th>Not serious</th>
<th>Not serious</th>
<th>Not serious</th>
<th>Not serious</th>
<th>Moderate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females patients preferred to use tincture and topical preparations and less preferred to use vaporizing and smoking preparations compared with males. (21)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients who used cannabis both recreationally and medically preferred smoking and vaporizing, while those who used cannabis medically only preferred smoking, vaporizing, tinctures, and edibles. (21)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Experienced cannabis users preferred multiple administration routes compared with novice users. Smoking, vaporizing, and edibles were the most common preferred administration routes among both experience and novice users. (21)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[Mixed] Among chronic pain patients who are legal members of medical cannabis dispensaries, a minority of participants preferred using a joint, pipe, or bong, while some preferred vaporizers, edibles, or tinctures; very few preferred concentrates or topicals. In addition, very few participants reported unpleasant routes of administration as what they liked least about medical cannabis (35)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Most patients who have an advanced life-limiting illness preferred an oral form of medical cannabis.

Quantitative (25) 1 (68) Very serious Not serious Not serious Serious Not serious Low

2. Factors that influenced patient’s decision regarding use of medical cannabis

2.1 Factors influenced the choice of medical cannabis use

Most patients used medical cannabis because it improved the management of symptoms associated with pain, mental health and other medical conditions.

Mixed (35) 1(984) Serious risk Not serious Not serious Not serious Not serious Moderate
Patients viewed medical cannabis as an effective approach to managing symptoms with or without other medications (20, 22, 23), including pain (20, 22, 23), disrupted sleep, poor appetite, and nausea (20). Patients reported that cannabis improved emotional and mental well-being by reducing anxiety, depression and stress (20). Patients also reported that cannabis allowed them to sleep, focus and function (28). Most patients reported that cannabis facilitated a state of relaxation in which pain could be dealt with in a more tolerable form (28).

However, patients found that medical cannabis use sometimes made it difficult to manage their medication regimen (23).
Most patients were motivated to use medical cannabis to reduce other prescription medications. Chronic pain patients who used both medical cannabis and prescription medications believed that medical cannabis was effective for pain relief and were motivated to use medical cannabis to decrease the amount of prescribed medications they used (27).
Patients with a range of chronic medical conditions (22) believed that medical cannabis managed pain symptoms and were motivated to use medical cannabis to decrease the amount of prescribed medications they used (22).

| Qualitative (22) | 1 (30) | No or very minor concerns | NA | No or very minor concerns | Moderate concerns | No or very minor concerns | Moderate |
The majority of patients expressed that their cannabis use was influenced by positive social consequences, such as social support from friends and family.

[Quantitative] A majority of patients agreed that cannabis for medical use would not cause disagreements or relationship problems with their loved ones (25). Most participants reported that their family members were supportive of their use, and the majority reported that their medical providers were supportive of their use (31,34).

| Quantitative (25,31,34) | 2 (2104) | Serious risk | Not serious | Not serious | Not serious | Not serious | Moderate |
Most patients expressed concerns with using cannabis when describing a range of adverse effects from use of medical cannabis.

Concerns about medical cannabis included concerns about side effects, addiction, tolerance, losing control or acting strangely, and were related to unwillingness to use cannabis (27). Patients who used cannabis to manage their pain had greater feelings of anxiety, and increased catastrophic thinking (26). Among those who were unwilling to use cannabis, increased age was related to more concerns about medical cannabis, including concerns of losing control (26). Increased age also impacted beliefs that cannabis was a useful medication to treat pain (27). Some patients reported that they were concerned about unpleasant physical or emotional symptoms suggestive of withdrawal after stopping medical cannabis use (31, 34). Some patients were concerned about mental or physical dependence to medical cannabis; however, most did not perceive themselves as addicted to medical cannabis (31, 34). Concerns about addiction were associated with unwillingness to use medical cannabis (26).

Some patients who were legal members of medical cannabis dispensaries reported adverse physical, cognitive, and emotional effects of medical cannabis, as well as people’s negative and stigmatizing values towards medical cannabis (35).
Patients commonly reported lack of concentration, poor memory and sleepiness as consequences of medical cannabis use. Participants also reported minor consequence which included eating too much, coughing, and weight gain. Seizures and anaphylaxis from an allergic reaction were described as severe consequences from use (20).

Some patients were concerned that, while medical cannabis helped with pain management, it might lead addiction (23). Patients with a history of addiction were concerned that medical cannabis use could pose a threat to their sobriety (23).

<table>
<thead>
<tr>
<th>Qualitative (20, 23)</th>
<th>2 (196)</th>
<th>Moderate concerns</th>
<th>No or very minor concerns</th>
<th>No or very minor concerns</th>
<th>Minor concerns</th>
<th>No or very minor concerns</th>
<th>Moderate concerns</th>
</tr>
</thead>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
Most patients expressed that their cannabis use was influenced by negative social consequences, such as stigma. Patients who were comfortable with their cannabis use for pain had a significant concern over the use of cannabis leading to relationship problems or disagreements with loved ones (25). Some patients agreed that medical cannabis would make them vulnerable to attack and theft by substance abusers. A minority of patients agreed that medical cannabis would cause problems with the law, and that they may be arrested or charged with possession of cannabis (25). Some patients expressed concerns about others’ opinions towards their used of cannabis-related products (31,34).

<table>
<thead>
<tr>
<th>Mode</th>
<th>Description</th>
<th>Count (n)</th>
<th>Risk</th>
<th>Note 1</th>
<th>Note 2</th>
<th>Note 3</th>
<th>Note 4</th>
<th>Note 5</th>
<th>Note 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantitative</td>
<td>Patients who were comfortable with their cannabis use for pain had a significant concern over the use of cannabis leading to relationship problems or disagreements with loved ones (25). Some patients agreed that medical cannabis would make them vulnerable to attack and theft by substance abusers. A minority of patients agreed that medical cannabis would cause problems with the law, and that they may be arrested or charged with possession of cannabis (25). Some patients expressed concerns about others’ opinions towards their used of cannabis-related products (31,34).</td>
<td>4 (3153)</td>
<td>Serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Moderate</td>
<td></td>
</tr>
</tbody>
</table>
Commonly reported negative social consequences included judgment from others as a result of use and “stoner” or “pothead” stereotypes (20, 32). Some patients reported that stigma affected the way they asked healthcare providers about cannabis as a treatment option, the ability to seek out medical cannabis as a treatment option, the location at which they purchased cannabis, and their ability to use cannabis in public. Patients who reported these factors tended to take longer to seek out cannabis as a treatment option, conceal their use, and would not speak to healthcare providers about cannabis (32).

The cost, legal status, and accessibility of medical cannabis influenced patients’ decisions to use medical cannabis. Some patients were concerned about the cost of medical cannabis and some were concerned about the legal status and accessibility of medical cannabis (31). Some patients reported that they would use medical cannabis if they had access to it (24). When making decisions about medical cannabis, the majority of patients relied on information from doctors, followed by the internet and friends or family (31, 34).

<table>
<thead>
<tr>
<th>Commonly reported negative social consequences</th>
<th>Qualitative (20, 32)</th>
<th>2 (168)</th>
<th>Moderate concerns</th>
<th>No or very minor concerns</th>
<th>No or very minor concerns</th>
<th>Minor concerns</th>
<th>No or very minor concerns</th>
<th>Moderate concerns</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>The cost, legal status, and accessibility of medical cannabis influenced patients’ decisions to use medical cannabis.</th>
<th>Quantitative (24, 31), Mixed (35)</th>
<th>3 (2599)</th>
<th>Serious risk</th>
<th>Not serious</th>
<th>Not serious</th>
<th>Not serious</th>
<th>Not serious</th>
<th>Moderate concerns</th>
</tr>
</thead>
</table>
Some patients felt that the cost of medical cannabis was too high, potentially limiting their access (20), while some reported that the legalization of medical cannabis improved access and influenced their decisions to purchase medical cannabis for symptom relief (20). Other patients found changes in policies related to medical cannabis difficult to navigate and wanted assistance to access medical cannabis (23).

### 2.2 Factors influencing the choice of different preparations of medical cannabis
Patients chose medical cannabis products mainly based on cannabinoid content, recommendations from dispensary employees, described effects, and cannabis variety (i.e. indica vs. sativa). A minority of patients selected cannabis based on visual properties and smell, and some patients were guided by recommendations from a friend, or name of the product. Recommendations from a medical professional was the least common factor that patients would consider when selecting medical cannabis (21).

When selecting medical cannabis products, patients consider the following factors: the most commonly factors were smell, delta 9-tetrahydrocannabinol (THC) content, hybrid indica/sativa species, indica species, how the flower looks (size, density of the flower, and/or trichome and shape, cannabidiol (CBD) content, and sativa species. Some patients reported varietal name as important factor for medical cannabis selection. (30)

Quantitative (21, 30)

2 (2750)

Serious risk

Not serious

Serious

Not serious

Not serious

Low
One study reported that long lasting effect of medical cannabis positively influenced patients choice of medical cannabis product (22). Another two studies reported that patients’ uncertain about how they could determine which species of cannabis might work best to manage their pain and side effects of medical cannabis (e.g. headaches, disorientation or the sensation of feeling “stoned,” coughing) negatively influence patients choice of medical cannabis product (23, 28).

<table>
<thead>
<tr>
<th>Qualitative (22, 23, 28)</th>
<th>3 (95)</th>
<th>No or very minor concerns</th>
<th>Moderate concerns</th>
<th>No or very minor concerns</th>
<th>Serious concerns</th>
<th>No or very minor concerns</th>
<th>Low</th>
</tr>
</thead>
</table>
Gender, reason for use, and level of use experience influenced the factors patients considered when selecting cannabis products. Quantitative (21)

Selection of cannabis product were influenced by gender, reason for use (e.g., medical only vs. medical and recreational), and cannabis experience level (e.g., novice vs. experienced). (21)

A higher proportion of males selected cannabis products based on cannabinoid content (i.e. THC or CBD potency, ratio of THC and CBD), cannabis variety (i.e. indica or sativa), visual properties, and smell. A higher proportion of females consulted with a medical professional when choosing cannabis products. (21)

Patients who use cannabis both medically and recreationally were more likely to select cannabis products based on THC or other cannabinoid content, cannabis variety, described effects, visual properties, smell, recommendation from friends, and the product name, while those who use cannabis medically were more likely use recommendations from dispensary employees or a medical professional. (21)

Novice users were more likely to select a cannabis product based on dispensary recommendation consult with a medical professional than experienced users, while experienced users chose products based on nearly all other selection factors including smell, visual properties, described effects, cannabinoid content (i.e. THC or CBD potency, ratio of THC and CBD), cannabis variety (i.e. indica or sativa) and name of medical cannabis product (21).
Abbreviations: CBD = cannabidiol; THC = delta-9-tetrahydrocannabinol.